DJS Law Group announced a class action lawsuit against ADMA Biologics for alleged violations of securities laws, including making false statements and failing to disclose related party transactions. The lawsuit claims ADMA manipulated sales figures to mislead investors between August 2024 and March 2026. Shareholders who bought ADMA shares during this period are encouraged to join the case to recover losses, with a deadline to participate by August 10, 2026. This legal action highlights risks of corporate transparency and investor protection in the biotech sector.
Schall, Brown & Schwartz LLP has announced a class action lawsuit against ADMA Biologics for alleged securities violations including false statements, undisclosed related party transactions, channel stuffing to inflate revenue, and poor internal cont...
Bernstein Liebhard LLP is investigating whether certain directors and officers of ADMA Biologics, Inc. breached their fiduciary duties to the company and its shareholders. The investigation aims to determine if the leadership acted in shareholders' b...
Berger Montague PC is investigating ADMA Biologics' Board of Directors for potential breaches of fiduciary duty related to alleged channel-stuffing practices. The firm suspects ADMA inflated revenue growth by pushing more of its flagship product, ASC...
